Fig. 7

Biomarkers of clinical outcome and trastuzumab responsiveness. DEGs in BTSH and BTSH compared to parental BT474 cell line were determined by microarrays analyses. To identify biomarkers of clinical outcome and trastuzumab response to two different strategies were followed. First, the role of DEGs with “inverse amount” on prognosis and trastuzumab response in HER2+ breast cancer patients was evaluated by KM plotter and ROC plotter, respectively. On the other hand, DEGs were overlapped with transcriptomic data from PAMELA clinical trial patients’ tumor samples and response to dual HER2 blockade was assessed